Akeso is betting a dual-target ADC can break through breast cancer’s increasingly crowded treatment field
Akeso starts Phase II testing of AK146D1 plus ivonescimab in advanced breast cancer. See what the dual-target ADC strategy must prove.
Pharma & Biotech
Pharma & Biotech
Ivonescimab delivers 80% response in TNBC: Is Akeso redefining PD-1 treatment?
Ivonescimab shows 80 percent response in TNBC Phase II study. Explore how Akeso’s bispecific strategy could reshape PD-1 therapy in first-line settings.